7P4D image
Entry Detail
PDB ID:
7P4D
Keywords:
Title:
Crystal Structure of Agd31B, alpha-transglucosylase in Glycoside Hydrolase Family 31, in complex with covalent Cyclophellitol Sulfamidate probe KK130
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2021-07-11
Release Date:
2022-07-27
Method Details:
Experimental Method:
Resolution:
1.85 Å
R-Value Free:
0.22
R-Value Work:
0.18
Space Group:
P 6 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Oligosaccharide 4-alpha-D-glucosyltransferase
Chain IDs:A (auth: AAA)
Chain Length:836
Number of Molecules:1
Biological Source:Cellvibrio japonicus Ueda107
Primary Citation
1,6- epi-Cyclophellitol Cyclosulfamidate Is a Bona Fide Lysosomal alpha-Glucosidase Stabilizer for the Treatment of Pompe Disease.
J.Am.Chem.Soc. 144 14819 14827 (2022)
PMID: 35917590 DOI: 10.1021/jacs.2c05666

Abstact

α-Glucosidase inhibitors are potential therapeutics for the treatment of diabetes, viral infections, and Pompe disease. Herein, we report a 1,6-epi-cyclophellitol cyclosulfamidate as a new class of reversible α-glucosidase inhibitors that displays enzyme inhibitory activity by virtue of its conformational mimicry of the substrate when bound in the Michaelis complex. The α-d-glc-configured cyclophellitol cyclosulfamidate 4 binds in a competitive manner the human lysosomal acid α-glucosidase (GAA), ER α-glucosidases, and, at higher concentrations, intestinal α-glucosidases, displaying an excellent selectivity over the human β-glucosidases GBA and GBA2 and glucosylceramide synthase (GCS). Cyclosulfamidate 4 stabilizes recombinant human GAA (rhGAA, alglucosidase alfa, Myozyme) in cell medium and plasma and facilitates enzyme trafficking to lysosomes. It stabilizes rhGAA more effectively than existing small-molecule chaperones and does so in vitro, in cellulo, and in vivo in zebrafish, thus representing a promising therapeutic alternative to Miglustat for Pompe disease.

Legend

Protein

Chemical

Disease

Primary Citation of related structures